abstract |
The invention relates to a method for prognosing SCA in a subject, the method of determining plasma concentrations of MIF and Nt-proBNP (or BNP) in a sample from the subject, to diagnose SCA when plasma concentrations of subject are greater than a plasma concentration of MIF and Nt-proBNP (or BNP) reference, and prognose the importance of SCA from the plasma concentrations of MIF and Nt-proBNP (or BNP) of the subject. The invention also relates to a method of treating SCA in a subject, device, kit and cardiac biomarker relating to SCA prognostic methods. |